期刊文献+

7-氨基-6-硝基-[1,2,5]噁二唑并[3,4-b]吡啶-1-氧化物的胺化开环反应及产物的抗肿瘤活性

Convenient Aminative Ring-Opening Reaction of 7-Amino-6-nitro[1,2,5]oxadiazolo[3,4-b]pyridine-1-oxide and Antitumor Activity of Corresponding Products
原文传递
导出
摘要 7-氨基-6-硝基-[1,2,5]噁二唑并[3,4-b]吡啶-1-氧化物(1)与胺在温和条件下反应,氧化呋咱环开环,释放一分子次硝酸,得到了蓝绿色的开环产物2-胺取代的-3-亚硝基-4-氨基-5-硝基吡啶5a^5f.发现化合物1中的6-位硝基对其氧化呋咱开环起到关键作用.利用~1H NMR,^(13)C NMR和HRMS对目标化合物进行了结构表征.用四甲基偶氮唑盐(MTT)法测试了目标化合物体外抑制人肺癌细胞株(H522)和脑胶质瘤细胞株(U87)两种肿瘤细胞的增殖活性.测试结果显示,所有目标化合物均表现较强的体外肿瘤细胞抑制活性. Reaction of 7-amino-6-nitro[1,2,5]oxadiazolo[3,4-b]pyridine-1-oxide (1, namely pyridofuroxan) with ammonia or/and amines under mild conditions let to the corresponding 5-nitro-3-nitroso-2,4-diaminopyridine 5a-5f. It is shown that the ring-opening reactivity of pyridofuroxan 1 was significantly affected by the 6-nitro substituent. The structures of all target compounds were identified by 1H NMR, 13C NMR and HRMS. The biological evaluation was performed on human lung cancer cell line (H522) and glioma cell line (U87) by 3-(4,5-dimethylthigal-2-yl)-2,5-(diphenyltetragalium) bromide (MTT) assay. The results suggested that all of the target compounds exhibited potent anti-tumor activities in vitro.
出处 《有机化学》 SCIE CAS CSCD 北大核心 2016年第9期2236-2241,共6页 Chinese Journal of Organic Chemistry
基金 国家自然科学基金(No.21102125)资助项目~~
关键词 吡啶并氧化呋咱 胺化开环反应 3-亚硝基吡啶 互变异构体 抗肿瘤活性 pyridofuroxans aminative ring-opening reaction 3-nitrosopyridine tautomer anticancer activity
  • 相关文献

参考文献9

  • 1Cerecetto, H.; Gonzfilez, M. Benzofuroxan and Furoxan. Chemistry and Biology, Bioactive Heterocycles IV, Springer Berlin Heidel- berg, 2007, p. 265.
  • 2Sartini, S.; Coseonati, S.; Marinelli, L.; Barresi, E.; Di Maro, S.; Simorini, E; Taliani, S.; Salerno, S.; Marini, A. M.; Da Settimo, F.; Novellino, E.; La Motta, C. J. Med. Chem. 2012, 55(23), 10523.
  • 3邓艳君,石静波,姜力勋,高静,姚其正.嘧啶并呋咱核苷衍生物的制备及其活性初探[J].化学学报,2006,64(18):1911-1915. 被引量:10
  • 4Ma, C.; Wang, Y.; Hou, K.; Liu, Z.; Yao, Q. Z. Chin. J. Org. Chem. 2013, 31(10), 1299.
  • 5Tannant, G.; Wallace, G. M. J. Chem. Soc., Chem. Commun. 1982, 4), 267.
  • 6An'is, C. E.; Boyle, F. 1".; Calvert, A. H.; Curtin, N. J.; Endicott, J. A.; Garman, E. F.; Gibson, A. E.; Golding, B. T.; Grant, S.; Griffin, R. J. J. Med. Chem. 2000, 43(15), 2797.
  • 7Sayle, K. L.; Bentley, J.; Boyle, F. T.; Calvert, A. H.; Cheng, Y.; Curtin, N. J.; Endicott, J. A.; Golding, B. T.; Hardcastle, L R.; Jewsbury, E; Mesguiche, V.; Newell, D. R.; Noble, M. E. M.; Par- sons, R. J.; Pratt, D. J.; Wang, L. Z.; Griffin, R. J. Bioorg. Med. Chem. Lett. 2003, 13(18), 3079.
  • 8Lowe-Ma, C. K., Nissan, R. A., Wilson, W. S. J. Org. Chem. 1990, 55(12), 3755.
  • 9Cmoch, P.; Kamiehski, B.; Kamiefska-Trela, K.; Stefaniak, L.; Webb G. A. J. Phys. Org. Chem. 2000, 13(8), 480.

二级参考文献14

  • 1Sako,M.; Oda,S.; Ohara,S.; Hirota,K.; Maki,Y.J.Org.Chem.1998,63,6947.
  • 2Reiss,C.S.; Komatsu,T.J.Virol.1998,72,4547.
  • 3de Clercq,E.; Tulkens,P.Curr.Opin.Pharmacol.2004,4,429.
  • 4Cresswell,R.M.; Wood,H.C.S.J.Chem.Soc.1960,4768.
  • 5Temple,C.; Kussner,C.L.; Montgomery,A.J.Org.Chem.1968,33,2086.
  • 6Dickey,J.B.; Gray,A.R.Org.Synth.1943,CV 2,60.
  • 7Nubel,G.; Pfleiderer,W.Chem.Ber.1962,95,1605.
  • 8Daves,G.D.; Robins,R.K.; Cheng,C.C.J.Am.Chem.Soc.1962,84,1724.
  • 9Nutiu,R.; Boulton,A.J.J.Chem.Soc.,Perkin Trans.1 1976,1327.
  • 10Vorbrueggen,H.; Run-Pohlenz,C.In Organic Reactions.Vol.55,Ed.:Paquette,L.A.,John Wiley & Sons,Inc.,Berlin,2000,pp.12~17.

共引文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部